Supercharged donor cells take on lymphoma in early trial

NCT ID NCT06176690

Recruiting now Disease control Sponsor: Baylor College of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 21, 2026 · Updated 2 times

Summary

This early-phase trial tests a new approach for people with certain lymphomas that have come back or not responded to treatment. Researchers take immune cells from healthy donors, modify them to recognize and attack CD30-positive cancer cells, and add a molecule (C7R) to boost their activity. The cells are given as a one-time infusion, and the study aims to see if this is safe and whether it can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: C7R-modified CD30-targeting CAR T cells from healthy donors
What this could lead to: If it works, this could offer a new treatment option for people with lymphomas that have not responded to standard therapy.
What could go wrong: This is a very early Phase 1 trial with only 90 participants, so safety and effectiveness are not yet proven. There are risks of serious side effects like cytokine release syndrome or graft-versus-host disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

aggressive B-cell non-Hodgkin lymphoma ALK-negative anaplastic large cell lymphoma ALK-positive anaplastic large cell lymphoma anaplastic large cell lymphoma diffuse large B-cell lymphoma extranodal nasal NK/T cell lymphoma Hodgkins lymphoma mature T-cell and NK-cell non-Hodgkin lymphoma non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ANAPLASTIC LARGE CELL LYMPHOMA, ALK-NEGATIVE ANAPLASTIC LARGE CELL LYMPHOMA, ALK-POSITIVE ANAPLASTIC LARGE CELL LYMPHOMA, T CELL AND NULL CELL TYPE CD30-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA HODGKIN LYMPHOMA NON-HODGKIN LYMPHOMA PERIPHERAL T-CELL LYMPHOMA

Contacts and locations

Locations

Houston Methodist Hospital
RECRUITING

Houston, Texas, 77030, United States
Texas Children's Hospital
NOT_YET_RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.